Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Venkatesh Rudrapatna (NPI 1104012996)

Field	Value
Entity Type	Individual
Organization	Venkatesh Rudrapatna
Address	1111 Duff Avenue
City	Ames
State	IA
ZIP	50010
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 14, 2007

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This provider generates $3.4M in lifetime Medicare revenue and has no Medicaid billing on file, making the practice effectively single-payer (Medicare) from the claims data available. The absence of any Medicaid activity means payer-mix analysis and revenue exposure are concentrated almost entirely on Medicare reimbursement patterns.

Revenue is highly concentrated in a few high-cost injectable oncology products: the top three Medicare codes account for 71.4% of total Medicare revenue. Specifically, J9271 (pembrolizumab) accounts for $1.4M (43.2%), J9144 (daratumumab) accounts for $656.6K (20.2%), and J0897 (denosumab) accounts for $259.2K (8.0%).

The code mix indicates a specialist hematology/oncology infusion operation centered on biologic and chemotherapy administration. High-revenue drug codes J9271 and J9144 plus chemotherapy administration codes such as 96413, 96417 and G0498 and infusion supplies codes 96365/96367 point to an onsite infusion/service line that delivers immunotherapy, monoclonal antibody treatments, and associated supportive care.

Competitive standing for the top agents is strong for certain drugs: J9271 (pembrolizumab) ranks #95 of 1841 nationally (95th percentile) and is described as notably above typical national volume, while J0897 (denosumab) ranks #581 of 10057 (94th percentile) and is also described as notably above typical national volume. By contrast, J9144 (daratumumab) ranks #67 of 615 (89th percentile) but is described as having typical, unremarkable volume for this code versus national peers, suggesting leadership in some high-cost drugs but not uniformly dominant across all biologic agents.

Outpatient evaluation-and-management activity is unusually high relative to peers, implying substantial clinic throughput supporting infusion services: 99213 has 2.1K claims and ranks #702 of 457151 (100th percentile) labeled an extreme outlier, far above typical national volume, and 99214 has 1.1K claims and ranks #9068 of 479517 (98th percentile) also labeled an extreme outlier. These patterns indicate heavy office-based visit volume for follow-up, management, and pre-/post-infusion evaluation.

Ancillary and supportive-service codes align with an integrated treatment workflow: lab panels (80053, 1.9K claims), CBCs (85025, 1.9K claims), and supportive drugs such as J2506 (pegfilgrastim) and J1561 (immune globulin) are present on the top code list. Infusion-related add-on and continuation codes such as 96417 (243 claims, 96th percentile noted as notably above typical) and 96367 (838 claims, 97th percentile, notably above typical) further reinforce that the practice manages multi-drug infusion sessions and monitoring onsite.

The provider’s revenue profile shows concentration risk tied to reimbursement and utilization of a small set of high-cost agents — notably J9271 alone represents $1.4M and 43.2% of Medicare revenue — which means changes to coverage, utilization, or pricing for those drugs would disproportionately affect revenue. Given the lack of Medicaid billing, any shifts in Medicare policy or site-of-care reimbursement could have outsized operational and financial impact.

The NPI was enumerated on 2007-09-14 (~19 years ago), indicating a long-tenured practitioner. Combined with the high visit volumes and substantial infusion drug billing, this tenure supports the interpretation of an established oncology practice with sustained referral and treatment activity in the Ames, IA market.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

88 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,600	$40	$1.4M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	17,280	$40	$656.6K
J0897	Injection, denosumab, 1 mg	14,400	$20	$259.2K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	6,580	$40	$250K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	2,110	$60	$132.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,100	$90	$100.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	900	$90	$78.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	810	$90	$75.8K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	27,980	$1	$56K
J1439	Injection, ferric carboxymaltose, 1 mg	48,750	$1	$48.8K

Showing 1–10 of 88

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Venkatesh Rudrapatna — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

88 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	30	17,200	$40	$902.3K
J9144	2	10	9,900	$40	$476.8K
J1561	1	10	4,150	$40	$170.9K
J0897	8	190	1,920	$20	$74.1K
J0881	3	10	15,520	$1	$43.2K
J1439	3	10	41,250	$1	$39.7K
J2506	1	20	440	$80	$38.9K
96413	3	80	210	$90	$24K
J9217	15	50	140	$130	$23.4K
91322	406	580	80	$140	$15.2K

Showing 1–10 of 88

Related Providers

Other providers that share a Tax Identification Number (TIN) with Venkatesh Rudrapatna, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Fairview Health Services	MN	General Acute Care Hospital	$0	$90.4M
Fairview Health Services	MN	Land Ambulance	$2.3M	$48.5M
Regions Hospital	MN	General Acute Care Hospital	$0	$44.4M
Fairview Express Care	MN	Specialist	$0	$33.1M
Fairview Health Services	MN	General Acute Care Hospital	$0	$30M
Mcfarland Clinic PC	IA	Multi-Specialty Clinic/Center	$0	$26.7M
Fairview Health Services	MN	Emergency Medicine Physician	$0	$26.6M
Fairview Health Services	MN	General Acute Care Hospital	$0	$17.2M
Regions Hospital	MN	Emergency Medicine Physician	$0	$15.1M
Fairview Health Services	MN	Durable Medical Equipment & Medical Supplies	$0	$14.4M

Nearby Providers

Other providers in the same ZIP code as Venkatesh Rudrapatna, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mainstream Living, Inc.	IA	Social Worker	$0	$134.3M
Youth And Shelter Services, Inc.	IA	Counselor	$0	$11.4M
Mary Greeley Medical Center	IA	General Acute Care Hospital	$0	$9.1M
Mary Greeley Medical Center	IA	Land Ambulance	$0	$4.4M
Sreenath Kodali	IA	Hematology & Oncology Physician	$3.2M	$0
The Richmond Center	IA	Mental Health Counselor	$0	$2.4M
Sonam Patel	IA	Hematology & Oncology Physician	$1.8M	$0
Joseph Merchant	IA	Hematology & Oncology Physician	$1.8M	$0
Tracy Kangas	IA	Ophthalmology Physician	$1.1M	$0
Steven Anderson	IA	Ophthalmology Physician	$755.9K	$0

Venkatesh Rudrapatna — Billing Profile & Reimbursement Data

Sign up for Venkatesh Rudrapatna — Billing Profile & Reimbursement Data policy alerts

Venkatesh Rudrapatna — Billing Profile & Reimbursement Data

Sign up for Venkatesh Rudrapatna — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References